Ixabepilone Chinese instructions and instructions for use

1. Name

Chinese name: Ixabepilone

English name:Ixabepilone

Product name:IXEMPRA

Ixabepilone is a semi-synthetic microtubule stabilizer, a new anti-cancer chemotherapy drug, mainly targeted at patients with refractory breast cancer. It binds to tubulin and prevents the depolymerization of microtubules, thereby inhibiting the division and proliferation of cancer cells and has a strong anti-tumor effect. Ixabepilone is considered one of the important options for the treatment of advanced breast cancer, especially for patients after failure of other chemotherapy regimens.

2. Indications

Ixabepilone is primarily indicated for the treatment of adult patients with advanced or metastatic breast cancer. Ixabepilone is usually considered in patients who have had an inadequate response or poor tolerance to multiple chemotherapy regimens, such as anthracyclines or paclitaxels. The positioning of this indication makes it an important drug for second-line or third-line treatment, providing new opportunities for the treatment of drug-resistant or recurrent breast cancer.

3. Usage and dosage

The use of ixabepilone needs to be performed by experienced oncologists in specialized hospitals. The usual adult dose is 40 mg/m² administered intravenously every three weeks over approximately three hours. For patients whose body surface area (BSA) exceeds 2.2 m², the dose should be calculated based on 2.2 m² to avoid overdose and toxic side effects. Before injection, the patient's hematological indicators, liver and kidney functions, and overall physical condition need to be fully assessed to ensure safe medication.

During use, doctors will adjust the dose according to the patient's tolerance and blood picture changes, and closely monitor changes in the nervous system, cardiovascular system and hematological indicators. Common adverse reactions include peripheral neuropathy, leukopenia, fatigue, hair loss, and digestive system symptoms, so strict follow-up is required during treatment.

4. Precautions for clinical use

1. Pre-medication assessment: Patients need to undergo a comprehensive blood picture, liver and kidney function, cardiac function and previous drug use history evaluation.

2. Medication monitoring: Hematological indicators, neurological symptoms and blood pressure changes need to be monitored during intravenous injection and during the treatment cycle.

3. Adverse reaction management: When severe hematological abnormalities, increased risk of infection, or neuropathy occur, the dose should be adjusted promptly or treatment should be suspended.

4. Combined use: Ixabepilone can be used in combination with other chemotherapy drugs, but attention should be paid to drug interactions and superimposed toxicity.

5. Listing and Price

Ixabepilone was approved by the US FDA in October 2007. It is an original anti-cancer drug. Common specifications in overseas markets are 15mg and 45mg tablets or injections, with prices of approximately US$2,000 and US$6,000 respectively. It is worth noting that ixabepilone is not currently on the market in China, so it is not covered by domestic medical insurance reimbursement, and there is no domestic generic version. If patients want to use ixabepilone, they need to obtain it through formal overseas channels, and they need to undergo treatment under the guidance of a doctor to ensure safety and effectiveness.

Overall, ixabepilone is an innovative anti-tumor drug for advanced breast cancer, suitable for patients who cannot tolerate conventional chemotherapy regimens or have relapsed. Its unique microtubule stabilizing mechanism makes it valuable in the treatment of drug-resistant breast cancer. Although it has not yet been launched in China, its efficacy and safety have been verified in overseas clinical practice, providing a new treatment option for patients with advanced breast cancer.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html